Applied Genetic Technologies Corporation

The Applied Genetic Technologies Corporation is a publicly traded (NASDAQ:AGTC)[1] biotechnology company that is part of the NASDAQ Biotechnology Index. The company focuses on ophthalmologic genetic diseases. The company's technologies have the ability to cure debilitating genetic diseases which include achromatopsia, X-Linked Retinoschisis,[2][3] X-Linked Retinitis Pigmentosa,[4][5][6] and age-related macular degeneration.[7][8][9][10] The company has 6 products in various stages of development.[11]

References

  1. ↑ "Applied Genetic Technologies Corporation (AGTC)". NASDAQ.com. Retrieved 4 January 2016.
  2. ↑ Chen, Angela. "Biogen to Pay Applied Genetic $124 Million to Develop Eye-Disease Treatments". Wall Street Journal. Retrieved 4 January 2016.
  3. ↑ "AGTC Announces Data Evaluating the Natural History of Patients With X-Linked Retinoschisis at the 48th Annual Retina Society Meeting". Yahoo Finance. Retrieved 4 January 2016.
  4. ↑ "New therapy may treat form of blindness". The Independent Florida Alligator. Retrieved 4 January 2016.
  5. ↑ "Biogen enters eye-treatment arena with AGTC deal". Yahoo Finance.
  6. ↑ "Biogen enters eye-treatment arena with AGTC deal". Reuters. 2 July 2015. Retrieved 4 January 2016.
  7. ↑ "http://www.sciencedaily.com/releases/2015/12/151221111433.htm". www.sciencedaily.com. Retrieved 4 January 2016. External link in |title= (help)
  8. ↑ "Study reveals new genetic clues to macular degeneration". www.yourconroenews.com. Retrieved 4 January 2016.
  9. ↑ Ballie, Katherine. "Penn-Michigan State Team Develops Novel Gene Therapy for Achromatopsia". www.upenn.edu. Retrieved 4 January 2016.
  10. ↑ Whiteman, Honor. "Cure for rare form of color blindness steps closer with novel gene insight". Medical News Today. Retrieved 4 January 2016.
  11. ↑ "Finding Cures for Visual Disorders l Products". www.agtc.com. Retrieved 4 January 2016.

External links


This article is issued from Wikipedia - version of the Thursday, February 25, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.